Tumor-specific CD8+ T cells are key effectors of antitumor immunity but are often rendered
dysfunctional in the tumor microenvironment. Immune checkpoint blockade can restore …

Immune checkpoint blockade (ICB) therapies function by alleviating immunosuppression on
tumor-infiltrating lymphocytes (TILs) but are often insufficient to fully reactivate these …

Abstract Anti–PD-1/PD-L1 immune checkpoint blockade (ICB) therapy has revolutionized
the treatment of many types of cancer over the past decade. The initial therapeutic …

Immune checkpoint inhibitors against PD-1, PD-L1 and CTLA-4 have altered the treatment
paradigm for various types of cancers in the past decade. However, they offer clinical …

TGFβ signaling is associated with non-response to immune checkpoint blockade in patients
with advanced cancers, particularly in the immune-excluded phenotype. While previous …

Background Although immune checkpoint inhibitors have been a breakthrough in clinical
oncology, these therapies fail to produce durable responses in a significant fraction of …

T cell–stimulating cytokines and immune checkpoint inhibitors (ICI) are an ideal combination
for increasing response rates of cancer immunotherapy. However, the results of clinical trials …

Anti-PD-1 immune checkpoint blockers can induce sustained clinical responses in cancer
but how they function in vivo remains incompletely understood. Here, we combined intravital …

Treatments aiming to augment immune checkpoint blockade (ICB) in cancer often focus on T
cell immunity, but innate immune cells may have important roles to play. Here, we …

Successful cancer immunotherapies rely on a replete and functional immune compartment.
Within the immune compartment, T cells are often the effector arm of immune-based …